EP3060216A4 - Methods for treating hcv - Google Patents

Methods for treating hcv Download PDF

Info

Publication number
EP3060216A4
EP3060216A4 EP14856676.3A EP14856676A EP3060216A4 EP 3060216 A4 EP3060216 A4 EP 3060216A4 EP 14856676 A EP14856676 A EP 14856676A EP 3060216 A4 EP3060216 A4 EP 3060216A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating hcv
hcv
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14856676.3A
Other languages
German (de)
French (fr)
Other versions
EP3060216A2 (en
Inventor
Iok Chan Ng
Liangjun Lu
Tanya DEKHTYAR
Thomas Reisch
Rakesh L. Tripathi
Ron PITHAWALLA
Christine A. Collins
Tami J. Pilot-Matias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of EP3060216A2 publication Critical patent/EP3060216A2/en
Publication of EP3060216A4 publication Critical patent/EP3060216A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14856676.3A 2013-10-25 2014-10-24 Methods for treating hcv Withdrawn EP3060216A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895945P 2013-10-25 2013-10-25
PCT/US2014/062265 WO2015061742A2 (en) 2013-10-25 2014-10-24 Methods for treating hcv

Publications (2)

Publication Number Publication Date
EP3060216A2 EP3060216A2 (en) 2016-08-31
EP3060216A4 true EP3060216A4 (en) 2017-06-21

Family

ID=52993758

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14856676.3A Withdrawn EP3060216A4 (en) 2013-10-25 2014-10-24 Methods for treating hcv

Country Status (7)

Country Link
US (1) US20150119400A1 (en)
EP (1) EP3060216A4 (en)
JP (1) JP2016534082A (en)
CN (1) CN105658219A (en)
CA (1) CA2925328A1 (en)
MX (1) MX2016005393A (en)
WO (1) WO2015061742A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN110302361A (en) 2014-04-02 2019-10-08 艾伯维公司 The method for treating HCV
MX2016016127A (en) * 2014-06-06 2017-02-23 Abbvie Inc Crystal forms.
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
AU2016291154B2 (en) * 2015-07-08 2021-10-21 Abbvie Inc. Methods for treating HCV
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070416A1 (en) * 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
WO2014152635A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
WO2014152514A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Combination of two antivirals for treating hepatitis c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070416A1 (en) * 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
WO2014152635A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
WO2014152514A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Combination of two antivirals for treating hepatitis c

Also Published As

Publication number Publication date
US20150119400A1 (en) 2015-04-30
CN105658219A (en) 2016-06-08
MX2016005393A (en) 2016-08-11
EP3060216A2 (en) 2016-08-31
JP2016534082A (en) 2016-11-04
CA2925328A1 (en) 2015-04-30
WO2015061742A2 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
EP3076967A4 (en) Novel methods
EP3008155A4 (en) Biorefining method
EP2994140A4 (en) Methods for treating hcv infection
GB201309057D0 (en) Method
EP3060216A4 (en) Methods for treating hcv
HK1215164A1 (en) Treatment methods
EP3065728A4 (en) Novel methods
GB201309928D0 (en) Method
GB201301857D0 (en) Method
EP3095535A4 (en) Spin-molding apparatus
EP3082841A4 (en) Methods for treating an animal
GB201309654D0 (en) Method
GB201301233D0 (en) Method
GB201300409D0 (en) Method
GB201311385D0 (en) Method
GB201305714D0 (en) Method
GB201301094D0 (en) Method
EP3025973A4 (en) Sterilization method
EP3313398A4 (en) Methods for treating hcv
EP3035373A4 (en) Heat treatment method
EP3068226A4 (en) Novel methods
EP3030523A4 (en) Turboelectric coagulation apparatus
AU2014220484B2 (en) Methods
AU2013902599A0 (en) Treatment method
AU2013904171A0 (en) Method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170524

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7056 20060101ALI20170518BHEP

Ipc: A61K 31/53 20060101ALI20170518BHEP

Ipc: A61K 31/498 20060101AFI20170518BHEP

Ipc: A61K 45/06 20060101ALI20170518BHEP

Ipc: A61K 31/12 20060101ALI20170518BHEP

Ipc: A61P 31/14 20060101ALI20170518BHEP

Ipc: A61K 31/00 20060101ALI20170518BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171223